Immune-checkpoint blockade of CTLA-4 (CD152) in antigen-specific human T-cell responses differs profoundly between neonates, children, and adults

The monoclonal antibody against CTLA-4, Ipilimumab, is a first-in-class immune-checkpoint inhibitor approved for treatment of advanced melanoma in adults but not extensively studied in children. In light of the fact that the immune response early in life differs from that of adults, we have applied...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Aditya Arra, Maximilian Pech, Hang Fu, Holger Lingel, Franziska Braun, Christian Beyer, Myra Spiliopoulou, Barbara M. Bröker, Karen Lampe, Christoph Arens, Katrin Vogel, Mandy Pierau, Monika C. Brunner-Weinzierl
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Taylor & Francis Group 2021-01-01
Edice:	OncoImmunology
Témata:	ctla-4 adults neonates children cd40l multifunctional t-cells s. aureus
On-line přístup:	http://dx.doi.org/10.1080/2162402X.2021.1938475
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!